Australia's most trusted
source of pharma news
Posted 9 December 2021 AM
The TGA has said it is investigating potential contamination of rifampicin antibiotics in Australia, after sponsors of the products, Sanofi and Alphapharm, reported that all products circulating in the market contain traces of 1-methyl-5-nitrosopiperazine (MeNP).
Sanofi's Rifadin and Alphapharm's Rimycin are essential, first-line medicines for the treatment of tuberculosis and are also used to treat or prevent other serious infections including blood infections and leprosy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.